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ABSTRACT
Introduction: Bipolar spectrum disorder is a chronic,
episodic illness, associated with significant personal,
social and economic burden. It is estimated to affect
∼2.4% of the population worldwide and is commonly
associated with psychological and/or physiological
comorbidities. Osteoporosis is one such comorbidity, a
disease of bone that is asymptomatic until a fracture
occurs. This systematic review attempts to capture,
collate, assess and discuss the literature investigating
the association between bipolar spectrum disorder and
bone health.
Methods and analysis: We aim to identify articles
that investigate the association between bipolar
spectrum disorder and bone health in adults by
systematically searching the MEDLINE, PubMed, OVID
and CINAHL databases. Two independent reviewers will
determine eligibility of studies according to
predetermined criteria, and methodological quality will
be assessed using a previously published scoring
system. A meta-analysis will be conducted, and
statistical methods will be used to identify and control
for heterogeneity, if possible. If numerical syntheses
are prevented due to statistical heterogeneity, a best
evidence synthesis will be conducted to assess the
level of evidence for associations between bipolar
spectrum disorder and bone health.
Ethics and dissemination: Ethical permission will
not be required for this systematic review since only
published data will be used. This protocol will be
registered with PROSPERO. Findings of the review will
be published in a peer-reviewed scientific journal, and
will be presented to clinical and population health
audiences at national and international conferences.
INTRODUCTION
Bipolar spectrum disorder, a mental disorder
characterised by biphasic ﬂuctuations in
mood, is a severe, chronic, episodic illness,
which generally necessitates pharmacother-
apy and/or psychotherapy. It is estimated to
affect ∼2.4% of the population1 and has
been ranked the sixth leading cause of dis-
ability in the world, among individuals aged
15–44 years.2 The related direct and indirect
costs associated with bipolar spectrum dis-
order are substantial.3 4 The burden of
bipolar spectrum disorder is experienced on
many levels—by the sufferer, their immediate
family and friends and also by the healthcare
system. Symptom burden and disease course
is often worsened in the presence of psycho-
logical and/or physiological comorbidities.5 6
Psychiatric disorders, including bipolar
spectrum disorder, have been associated with
early mortality, with ∼60% of this excess mor-
tality due to chronic physical illness.7 A par-
ticularly common comorbidity of unipolar
depression is osteoporosis.8 9 Yet it is norma-
tively overlooked, due to being asymptomatic
until fracture occurs. Osteoporosis is a global
public health issue, estimated to affect nearly
49 million individuals in industrialised coun-
tries, with this on the rise as a consequence
of the ageing population.10 11 The rising
global economic burden related to the direct
and indirect costs of medical care and
rehabilitation of individuals with osteoporotic
fractures is concerning.12 13 Both clinically
diagnosed unipolar depression and depres-
sive symptoms have been shown to be
Strengths and limitations of this study
▪ This systematic review will explore a novel and
covert clinical area.
▪ It will comprehensively assess existing literature
that investigates associations between bipolar
spectrum disorder and bone health.
▪ Potential confounders and/or mediators of the
relationship will be identified.
▪ Two authors will independently confirm study
selection, and undertake data extraction and
methodological assessment.
▪ A potential limitation of this review may be the
paucity of data available due to this being a
nascent area of enquiry, and that there may be
much heterogeneity in available studies.
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associated with deﬁcits in bone mineral density (BMD),
bone loss over time and increased fracture risk in men
and women.9 14 15 Furthermore, antidepressants, in par-
ticular, selective serotonin reuptake inhibitors used in
treatment of depression, have also been shown to be
noxious to bone.16 Other psychotropic medication,
namely antipsychotics and anticonvulsants, have also
been shown to have a deleterious effect on bone.17–19 A
recent research synthesis with meta-analyses concluded
that depression should be considered a serious risk
factor for osteoporosis, based on aggregated data
showing BMD among individuals with depression to be
up to 7.3% lower.15 20 Another meta-analysis reported
depression to be associated with up to a 52% increased
risk of fracture.21 Whether this is true for bipolar spec-
trum disorder per se is yet to be determined.
Considering the previous research discussing the prob-
able association between unipolar depression and bone,
this review would essentially provide a starting point for
similar investigations in bipolar spectrum disorder. This
review will analyse the existing data, and this information
may provide a clearer background into bone fragility
associated with bipolar spectrum disorder, enabling the
details of this association to be further explored.
Objectives
This systematic review will:
1. Identify published studies that investigate the associ-
ation between bipolar spectrum disorder and bone
health, including BMD and fracture;
2. Evaluate the quality of the methodology used in each
of the studies eligible for inclusion in this review;
3. Collate the evidence, including identifying any poten-
tial confounding and/or mediating factors in the
association between bipolar spectrum disorder and
bone health;
4. Perform sensitivity analyses to account for differences
between (a) self-reported and diagnosed bipolar
spectrum disorder, (b) diagnostic criteria between
versions of the Diagnostic and Statistical Manual
(DSM) and/or International Classiﬁcation of
Diseases (ICD) and (c) bipolar disorders I and II;
5. Provide a comprehensive synthesis of the ﬁndings
using previously published methodology.
METHODS
Criteria for considering studies for this review
Articles resulting from cross-sectional, case–control and/
or longitudinal studies of bone health (deﬁned as BMD,
bone quality, osteoporosis and/or fracture), in adult
populations (≥18 years) with bipolar spectrum disorder
(deﬁned by self-report, medical records or diagnoses
based on any version of the Diagnostic and Statistical
Manual of Mental Disorders or International Statistical
Classiﬁcation of Diseases and Related Health Problems
criteria), inclusive of any sex or nationality, and
published in any year, will be considered as eligible for
this review.
Grey literature, case studies, theses and conference
presentations will be excluded. Baseline data from ran-
domised control trials will be included and treated as
cross-sectional analyses.
Search strategy and data extraction
In order to identify the relevant literature, we will under-
take an electronic search strategy to investigate research
databases from the disciplines of medical, health and
the social sciences (PubMed, OVID, CINAHL,
MEDLINE). The following medical subject headings will
be applied: “bipolar disorder” AND (“bone” OR “osteo-
porosis” OR “fracture” OR “bone density”), to identify
publications that match our eligibility criteria. For our
search strategy, we will also include the key word term of
‘bipolar spectrum disorder’.
No limits will be applied with regard to year of publi-
cation. For each database, where appropriate, relevant
truncation will be applied. One reviewer will apply the
search strategy and identify eligible literature for inclu-
sion by cross-checking with the predetermined eligibility
criteria. Two further reviewers will conﬁrm the eligibility
of those identiﬁed articles. Professional assistance would
be sought to interpret articles written in languages other
than English, in order to conﬁrm their relevance to the
eligibility criteria. Finally, the reference lists of eligible
studies will be manually searched by two reviewers.22
Assessment of methodological quality of included articles
The methodological scoring system of Lievense et al23
will be employed to assess the methodological quality of
included articles (tables 1 and 2). Based on those meth-
odological assessment criteria, each eligible study will be
scored, with each study given either a positive or nega-
tive score for each criterion. This process of scoring
methodological quality reﬂects cohort studies as the
most optimal study design, followed by case–control
studies and, ﬁnally, cross-sectional study designs. Two
reviewers will independently score the methodological
quality of each study; should these scores differ, the
reviewers will attempt to reconcile any differences, after
which a third reviewer would provide ﬁnal judgement, if
necessary. Each study will be ranked according to their
total score (%), and deemed as having higher methodo-
logical quality if scored above the median, as previously
published.24
For the meta-analyses, we will determine the popula-
tion with bipolar spectrum disorder to be our proxy
‘treatment’ group and apply Hunter-Schmidt’s
approach,25 whereby a pooled within-group SD will be
used. Effect size will be corrected for measurement
error by dividing the effect size by the square root of the
reliability coefﬁcient of the dependent variable, whereby
measurement error correction equals the effect size
divided by the square root of r.
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Presenting and reporting results
PRISMA guidelines26 will be adhered to, with regard to
the presentation of ﬁndings from this review, and this
protocol adheres to the PRISMA-P guidelines.27
Numbers and reasons pertaining to inclusion versus
exclusion of papers in the context of the predetermined
eligibility criteria will be presented in a QUOROM
diagram.28 Key information regarding factors involved in
the association between bipolar spectrum disorder and
bone health will be identiﬁed; these factors may include,
but will not be limited to, inﬂammatory markers, lifestyle
behaviours, socioeconomic status, medications and sub-
stance use. Our ﬁndings will be useful to inform and
reach a consensus as to the link between bipolar spec-
trum disorder and bone health.
A meta-analysis is planned; however, if a numerical
synthesis is not possible due to methodological hetero-
geneity, a ‘best evidence synthesis’ will be undertaken. A
‘best evidence synthesis’ would evaluate the level of evi-
dence identiﬁed, ranging from no evidence to strong
evidence (table 2), as previously published in the muscu-
loskeletal ﬁeld.24
We will also perform sensitivity analyses to account for
differences between (1) self-reported and diagnosed
bipolar spectrum disorder, (2) diagnostic criteria
between versions of the DSM and/or ICD and (3)
bipolar disorders I and II.
Dissemination
This protocol will be registered with PROSPERO, an
international database of health-related systematic review
protocols. The ﬁndings of our systematic review will be
published in a peer-reviewed scientiﬁc journal, and
results will be shared at national and/or international
conferences relevant to the ﬁeld of bipolar spectrum dis-
order and/or bone health.
Ethics
Since only published data will be used in this systematic
review, we do not require ethical permission. However,
ethical and governance standards will be strictly adhered
to, in matters of data management and in the presenta-
tion and discussion of our results.
Conclusion
To the best of our knowledge, this will be the ﬁrst sys-
tematic review to identify and evaluate the existing evi-
dence base regarding associations between bipolar
spectrum disorder and bone health; and determining
the nature of this relationship has both public health
and clinical implications. The ﬁndings of this review will
contribute to existing literature investigating other psy-
chiatric disorders and bone health, and will also provide
an evidence base on which resource allocation and clin-
ical and public health strategies aimed at reducing
burden associated with both osteoporosis and bipolar
spectrum disorder can be founded.
Author affiliations
1Deakin University, Geelong, Victoria, Australia
2Australian Institute for Musculoskeletal Science (AIMSS), The University of
Melbourne and Western Health, St Albans, Australia
Table 2 Method for determining the level of evidence for
best evidence synthesis, adapted from Lievense et al;
replicated from Brennan et al24
Level of
evidence
Criteria for inclusion in best evidence
synthesis
Strong evidence Generally consistent findings in:
Multiple high-quality cohort studies
Moderate
evidence
Generally consistent findings in:
▸ 1 high-quality cohort study and >2
high-quality case–control studies
▸ >3 high-quality case–control studies
Limited
evidence
Generally consistent findings in:
▸ A single cohort study
▸ 1 or 2 case–control studies or
▸ Multiple cross-sectional studies
Conflicting
evidence
Inconsistent findings in >25% of the
trials
No evidence No studies could be found
Table 1 Criteria list for assessment of study quality,
adapted from Lievense et al23
Item Criterion C/CC/CS
Study population
1 Uniform point (selection before disease
was present)
C/CC/CS
2 Cases and controls drawn from the
same population
CC
3 Participation rate >80% for cases/
cohort
C/CC/CS
4 Participation rate>80% for controls CC
Assessment of risk factor
5 Exposure assessment blinded C/CC/CS
6 Exposure measured identically for
cases and controls
CC
7 Exposure assessed prior to the
outcome
C/CC/CS
Assessment of outcome
8 Bone health assessed identically in
patients with bipolar spectrum disorder.
C/CC/CS
9 Presence of osteoporosis assessed
reproducibly
C/CC/CS
10 Osteoporosis identification assessed
according to BMD measurements
C/CC/CS
Study design
11 Prospective design used C/CC
12 Follow-up time >24 months C
13 Withdrawals <20% C
Analysis and data presentation
14 Appropriate analysis techniques used C/CC/CS
15 Adjusted for at least age and sex C/CC/CS
BMD, bone mineral density; C, applicable to cohort studies; CC,
applicable to case–control studies; CS, applicable to
cross-sectional.
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